McKesson Corporation
NYSE:MCKMedical - Distribution
-$28.96 today
- Market cap
- $125.21B
- Beta
- 0.32
- P/E (TTM)
- 19.3
- EPS (TTM)
- $39.00
- Dividend yield
- 0.44%
Volume 0.67M
Average 1.03M
MCK Interest Expense
Cost of servicing the company's debt during the period.
McKesson CorporationNYSE: MCK
Interest Expense · Q1 FY2027 · quarter ended Jun 2026
Interest expense growth accelerates
Q1 FY2027 interest expense of $77M rose 57.1% year over year, ahead of the -36.0% change in trailing-twelve-month interest expense. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Interest expense amounted to 0.1% of revenue in FY2026, unchanged from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +57.1% holds above the trailing-twelve-month pace of -36.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2026
- 247M USD
- Year-over-year change
- -3.5%
- 4-year CAGR
- +8.5%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 247M | -3.5% |
| FY2025 | 2025-03-31 | 256M | +5.3% |
| FY2024 | 2024-03-31 | 243M | -2.0% |
| FY2023 | 2023-03-31 | 248M | +39.3% |
| FY2022 | 2022-03-31 | 178M | — |
Interest Expense vs competitors
How MCK compares with its peers on the latest reported figures
- MCK's LTM Jun 2026 interest expense of $153M is the 3rd highest of the 4 companies compared; the peer median is $341M.
- Its year-over-year change of -36.0% is the lowest of 4, against a peer median of +29.7%.
- Interest expense amounts to 0.0% of revenue for MCK, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497.77M | +36.5% | +21.9% | 0.1% | |
| LTM Sep 2026 | $341M | +29.7% | +60.6% | 0.1% | |
| LTM Jun 2026 | $153M | -36.0% | -0.1% | 0.0% | |
| LTM Mar 2026 | $136.75M | -3.8% | +0.1% | 5.0% | |
| Peer median (excluding MCK) | $341M | +29.7% | +21.9% | 0.1% | |
Competitors are the stored peer set for MCK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 263.97B | 276.71B | 308.95B | 359.05B | 403.43B |
| Cost of Revenue | 251.32B | 264.84B | 296.75B | 346.57B | 388.88B |
| Gross Profit | 12.65B | 11.87B | 12.2B | 12.49B | 14.55B |
| Gross Margin | 4.8% | 4.3% | 3.9% | 3.5% | 3.6% |
| Research & Development | 70M | 89M | 77M | 91M | 103M |
| Selling, General & Admin | 9.86B | 7.33B | 8.2B | 8.02B | (8.1B) |
| Operating Expenses | 9.93B | 7.42B | 8.28B | 8.11B | 8.1B |
| Depreciation & Amortization | 760M | 608M | 635M | 636M | 729M |
| EBITDA | 2.87B | 5.49B | 4.67B | 5.25B | 7.18B |
| EBITDA Margin | 1.1% | 2.0% | 1.5% | 1.5% | 1.8% |
| Operating Income | 2.72B | 4.45B | 3.93B | 4.37B | 6.45B |
| Operating Margin | 1.0% | 1.6% | 1.3% | 1.2% | 1.6% |
| Interest Income | 10M | 107M | 118M | 173M | 179M |
| Interest Expense | 178M | 248M | 243M | 256M | 247M |
| Other Income / Expenses | (795M) | 177M | (138M) | (13M) | (253M) |
| Income Before Tax | 1.93B | 4.63B | 3.79B | 4.36B | 6.2B |
| Pre-Tax Margin | 0.7% | 1.7% | 1.2% | 1.2% | 1.5% |
| Income Tax Expense | 636M | 905M | 629M | 878M | 1.1B |
| Net Income | 1.11B | 3.56B | 3B | 3.3B | 4.76B |
| Net Margin | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| EPS (Basic) | 7.31 | 25.23 | 22.54 | 25.86 | 38.55 |
| EPS (Diluted) | 7.23 | 25.04 | 22.39 | 25.72 | 38.38 |
| Weighted Avg Shares | 152.3M | 141.1M | 133.2M | 127.4M | 123.6M |
| Weighted Avg Shares (Diluted) | 154.1M | 142.2M | 134.1M | 128.1M | 124.1M |
McKesson Corporation
NYSE:MCK
Intrinsic Alpha fair value
Locked
Current Price
$1,084.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.